Member Info for Laura2022

Apart from KingH who is always willing to reply /discuss I I not sure why 2 or 3 people here are unwilling to reply/engage over the last few weeks

I woukd have thought it would be common courtesy ,particularly when we qll want the sake goal

Pretty poor manners be be fair

Apologies for the outburst , maybe I'm just weary

Thankyou

201 still moving along. Can anyone else confirm if I was right in seeing that the slide on 201 expected conclusion in June? Was working while I had the presentation on.

Was this confirmed please

Many thanks all

Ralph, in that case .....

Try to post on here...wish we got £5mln deal with Glaxo inntjet case :)

:) :)

L

I for one really appreciate the great insight shown by yourself and other s

Thanks

L

Morning Trench

Was he a main scientist ?, very interesting comments regarding valuations as since 2017 the client base and development is much more advanced you would say

I am lost now ..sorry

What does matters pertaining mean (I'm being dozy)

I don't know the significance of Hitiesh only that,as stated previously,it was covered in the Q and A With regards in house full time appointments

Ever since 25th April all you have done has been very negative

Yet the oboy public released info was a trading update to say £350k would be mostly recognised after June and therefore highest order book for q start ofba year and yesterday's news that Chris has left which a) streamlines the BOD b) saves costs

This was your posts on late April

Let the traders get there few % that’s the market and that needs to be accepted.

The MC needs / will rerate and will be multiples of the current.

Some will gain a few % some will gain hundreds.

Is what it is….

I don't understand why someone would go full U turn kingH comapred to April where you were very positive and have often said how impressed with PS?

Do u not hold anymore?

Prior to joining us, Dr Sargent held a senior management role at global consultancy business Syneos Health Inc (NASDAQ: SYNH), leading large teams of professionals and servicing a variety of clients in the biopharmaceuticals space.

I would doubt that Ralph given both Jim and Pete public commitment to working tougher

I often eodnrrd what CC actually did...so I'm glad dead wood is ruthlessly being stripped + save on his salary to focus only on REVENUE GENERATING

The IP out licence looks interesting

Pete making his plans and streamlining

Company continues to focus on expenditure directly linked to revenue generating positions.

 

In his time at the Company, Dr Chassagnole has made important contributions in the development of the Company's client offering, the publication of thought leadership and the securing of grants.

 

In order to ensure a smooth transition, the Company will enter into a consulting agreement with Dr Chassagnole that would enable it to continue to take advantage of his scientific expertise and experience as required following the end of his formal employment.  In addition, the Company has entered into an IP Licensing Agreement with Dr Chassagnole under which certain systems biology models and  software, no longer used or commercialised by the Company, and unrelated to the Company's Virtual Tumour software, will be licensed on a non-exclusive basis to a company set up and owned by Dr Chassagnole.  Under this agreement, the Company will receive a 2-5% royalty on any gross sales that may be derived from this IP up to a maximum amount of £75k per annum.

Good afternoon Trench

Maybe just ring directly ?

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Https://www.bbc.co.uk/news/articles/cl77qvd2krgo

GPL risen 1000% for some patent applications

PYC can hopefully catch a wind

They are the way forward and the FDA has recently ruled that all new drug discoveroe should proof that they have used drug development computer /statistics modleking

PYC does exactly this (similar to GPL but has over 50 clients )

Amazing to see

Also taker a look at £1.5mln cap PYC and only small shares in issue who use A.i to speed up drug discovery and approval, one client they work with just sold a drug which PYC helped with for $1.5bln !!

Amazing to see

Days like this make investments worthwhile

Also taker a look at £1.5mln cap PYC who use A.i to speed up drug discovery and approval, one client they work with just sold a drug which PYC helped with for $1.5bln !!

Johnson & Johnson will pay a purchase price of $1.25 billion and will gain the full rights to develop, manufacture and commercialize NM26 globally 

Amazing news,hopefully other PYC clients will see the value we cam add to their lead drugs

The work with numab qmd Bicycle shows the real value PYC can offer

I asked at the last q and a if we could go for revenues sharing agreements